© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Galecto, Inc. (GLTO) stock declined over -3.56%, trading at $25.87 on NASDAQ, down from the previous close of $26.82. The stock opened at $27.09, fluctuating between $25.69 and $28.76 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 22, 2026 | 27.09 | 28.76 | 25.69 | 25.90 | 153.67K |
| Apr 21, 2026 | 26.43 | 27.08 | 25.77 | 26.82 | 189.55K |
| Apr 20, 2026 | 26.59 | 28.54 | 26.18 | 26.43 | 205.41K |
| Apr 17, 2026 | 27.85 | 27.93 | 26.29 | 26.60 | 388.38K |
| Apr 16, 2026 | 26.79 | 28.18 | 26.29 | 27.00 | 483.23K |
| Apr 14, 2026 | 27.00 | 28.57 | 25.80 | 26.73 | 325.5K |
| Apr 13, 2026 | 25.68 | 26.65 | 24.80 | 26.43 | 238.47K |
| Apr 10, 2026 | 27.09 | 27.88 | 25.55 | 25.82 | 287.22K |
| Apr 09, 2026 | 24.96 | 26.99 | 24.95 | 26.69 | 337.18K |
| Apr 08, 2026 | 25.17 | 27.29 | 25.17 | 25.60 | 151.28K |
| Apr 07, 2026 | 24.11 | 26.33 | 23.22 | 24.40 | 200.98K |
| Apr 06, 2026 | 24.81 | 26.14 | 24.35 | 24.57 | 167.13K |
| Apr 02, 2026 | 24.12 | 27.01 | 24.00 | 25.09 | 235.82K |
| Apr 01, 2026 | 25.45 | 26.72 | 24.58 | 25.08 | 145.68K |
| Mar 31, 2026 | 24.83 | 26.86 | 24.49 | 25.94 | 202.29K |
| Mar 30, 2026 | 25.83 | 26.17 | 23.41 | 24.27 | 240.98K |
| Mar 27, 2026 | 25.02 | 25.96 | 22.92 | 25.50 | 171.78K |
| Mar 25, 2026 | 24.63 | 26.11 | 23.54 | 24.96 | 113.94K |
| Mar 24, 2026 | 22.41 | 24.08 | 20.45 | 23.92 | 356.28K |
| Mar 23, 2026 | 17.81 | 23.18 | 17.66 | 23.05 | 337.88K |
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
| Employees | 5 |
| Beta | 1.57 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |